STEP THERAPY CRITERIA

DRUG CLASS XANTHINE OXIDASE INHIBITORS

BRAND NAME (generic)

ULORIC (febuxostat)

Status: CVS Caremark Criteria

Type: Initial Step Therapy; Post Step Therapy Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Uloric is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable.

For the safe and effective use of allopurinol, see allopurinol prescribing information.

Limitations of Use

Uloric is not recommended for the treatment of asymptomatic hyperuricemia.

INITIAL STEP THERAPY

If the patient has filled a prescription for at least a 30 day supply of allopurinol within the past 180 days under a prescription benefit administered by CVS Caremark, then the requested drug will be paid under that prescription benefit. If the patient does not meet the initial step therapy criteria, then the claim will reject with a message indicating that a prior authorization (PA) is required. The prior authorization criteria would then be applied to requests submitted for evaluation to the PA unit.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the chronic management of hyperuricemia in an adult patient with gout **AND**
 - The request is NOT for continuation of therapy

AND

- The patient has experienced an inadequate treatment response to a maximally titrated dose of allopurinol OR
- The patient has experienced an intolerance to allopurinol OR
- Treatment with allopurinol is contraindicated or inadvisable for the patient

OR

• The request is for continuation of therapy

AND

 The patient has achieved or maintained a positive clinical response since beginning treatment with the requested drug

REFERENCES

1. Uloric [package insert]. Lexington, Massachusetts: Takeda Pharmaceuticals America, Inc.; August 2020.

Uloric PA with Logic Policy 540-D 12-2022

©2022 CVS Caremark. All rights reserved.

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

- 2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2022; Accessed November 4, 2022.
- 3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: https://www.micromedexsolutions.com. Accessed November 4, 2022.
- 4. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. *Arthritis Rheumatol*. 2020;72(6):879-895.